Gliadin Nanoparticles as Carriers for the Oral Administration of Lipophilic Drugs. Relationships Between Bioadhesion and Pharmacokinetics
- 307 Downloads
Purpose. The aim of this work was to evaluate the bioadhesive properties of non-hardened gliadin nanoparticles (NPs) and cross-linked gliadin nanoparticles (CL-NP) in the carbazole pharmacokinetic parameters obtained after the oral administration of these carriers.
Methods. A deconvolution model was used to estimate the carbazole absorption when loaded in the different gliadin nanoparticles. In addition, the elimination rates of both adhered and non-adhered nanoparticulate fractions within the stomach were estimated.
Results. Nanoparticles dramatically increased the carbazole oral bioavailability up to 49% and provided sustained release properties related to a decrease of the carbazole plasma elimination rate. The carbazole release rates from nanoparticles (NP and CL-NP), calculated by deconvolution, were found to be of the same order as the elimination rates of the adhered fractions of nanoparticles in the stomach mucosa. In addition, good correlation was found between the carbazole plasmatic levels, during the period of time in which the absorption process prevails, and the amount of adhered carriers to the stomach mucosa.
Conclusion. Gliadin nanoparticles significantly increased the carbazole bioavailability, providing sustained plasma concentrations of this lipophilic molecule. These pharmacokinetic modifications were directly related to the bioadhesive capacity of these carriers with the stomach mucosa.
Unable to display preview. Download preview PDF.
- 1.M. A. Longer, H. S. Ch'ng, and J. R. Robinson. Bioadhesive polymers as platforms for oral controlled drug delivery III: Oral delivery of chlorothiazide using a bioadhesive polymer. J. Pharm. Sci. 74:406-411 (1985).Google Scholar
- 2.J. Kreuter. Peroral administration of nanoparticles. Adv. Drug Deliv. Rev. 7:71-86 (1991).Google Scholar
- 3.S. Sakuma, R. Sudo, N. Suzuki, H. Kikuchi, M. Akashi, and M. Hayashi. Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract. Int. J. Pharm. 177:161-172 (1999).Google Scholar
- 4.C. Durrer, J. M. Irache, F. Puisieux, D. Duchêne, and G. Ponchel. Mucoadhesion of latexes. II. Adsorption isotherms and desorption studies. Pharm. Res. 11:680-683 (1994).Google Scholar
- 5.P. K. Gupta, S. H. Leung, and J. R. Robinson. Bioadhesives/Mucoadhesives in drug delivery to the gastrointestinal tract. In V. Lenaerts, and R. Gurny (eds.), Bioadhesive Drug Delivery Systems, CRC Press, Boca Raton. FL; 1990, pp. 65-92.Google Scholar
- 6.C. M. Lehr. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 11:119-160 (1994).Google Scholar
- 7.S. Sakuma, N. Suzuki, H. Kikuchi, K. I. Hiwatari, K. Arikawa, A. Kishida, and M. Akashi. Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. Int. J. Pharm. 149:93-106 (1997).Google Scholar
- 8.P. Maincent, R. Le Verge, P. Sado, P. Couvreur, and J. P. Devissaguet. Disposition kinetics and oral bioavailability of vinca-min-loaded polyalkycyanoacrylate nanoparticles. J. Pharm. Sci. 75:955-958 (1986).Google Scholar
- 9.D. E. Chickering III, J. S. Jacob, T. A. Desai, M. Harrison, W. P. Harris, C. N. Morrell, P. Chaturvedi, and E. Mathiowitz. Bioadhesive microspheres: III. An in vivo transit and bioavailability study of drug-loaded alginate and poly(fumaric-co-sebacic anhydride) microspheres. J. Control. Release 48:35-46 (1997).Google Scholar
- 10.E. Mathiowitz, J. S. Jacob, Y. S. Jong, G. P. Carino, D. E. Chikering, P. Chaturvedi, C. A. Santos, K. Vijayaraghavan, S. Montgomery, M. Basset, and C. Morrell. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386:411-414 (1997).Google Scholar
- 11.Y. Akiyama, N. Nagahara, T. Kashihara, S. Hirai, and H. Toguchi. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative. Pharm. Res. 12:397-405 (1995).Google Scholar
- 12.Y. Akiyama, N. Nagahara, E. Nara, M. Kitano, S. Iwasa, I. Yamamoto, J. Azuma, and Y. Ogawa. Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites. J. Pharm. Pharmacol. 50:159-166 (1998).Google Scholar
- 13.M. A. Arangoa, G. Ponchel, A. M. Orecchioni, M. J. Renedo, D. Duchêne, and J. M. Irache. Bioadhesive potential of gliadin nanoparticulate systems. Eur. J. Pharm. Sci. 11:333-341 (2000).Google Scholar
- 14.M. A. Arangoa. New nanoparticulate dosage forms from gliadin: development and evaluation of the bioadhesive potential. Thesis, University of Navarra, Pamplona, 1999.Google Scholar
- 15.P. Ruelle, E. Sarraf, and U. W. Kesselring. Prediction of carbazole solubility and its dependence upon the solvent nature. Int. J. Pharm. 104:125-133 (1994).Google Scholar
- 16.M. A. Arangoa, M. A. Campanero, Y. Popineau, and J. M. Irache. Evaluation and characterisation of gliadin nanoparticles and isolates by reversed-phase HPLC. J. Cereal Sci. 31:223-228 (2000).Google Scholar
- 17.M. A. Arangoa, M. A. Campanero, Y. Popineau, and J. M. Irache. Electrophoretic separation and characterisation of gliadin fractions from isolates and nanoparticulate drug delivery systems. Chromatographia 50:243-246 (1999).Google Scholar
- 18.I. Ezpeleta, J. M. Irache, S. Stainmesse, C. Chabenat, J. Gueguen, Y. Popineau, and A. M. Orecchioni. Gliadin nanoparticles for the controlled release of all-trans-retinoic acid. Int. J. Pharm. 131: 191-200 (1996).Google Scholar
- 19.B. P. Imbimbo, E. Imbimbo, S. Daniotti, D. Verotta, and G. Bassotti. A new criterion for selection of pharmacokinetic multiexponential equations. J. Pharm. Sci. 77:784-789 (1988).Google Scholar
- 20.M. Rowland and T. N. Tozer. Clinical pharmacokinetics. Concepts and applications. Lea and Febiger, Philadelphia, 1995.Google Scholar
- 21.J. M. Lanao, M. T. Vicente, and M. L. Sayalero. Calculation of partial components of biovailability in slow release formulations using model-independent methods. Int. J. Pharm. 117:113-118 (1995).Google Scholar
- 22.D. P. Callender, N. Jayaprakash, A. Bell, V. Petraitis, R. Petratienes, M. Candelario, R. Schaufele, J. M. Dunn, S. Sei, T. J. Walsh, and F. M. Balis. Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits. Antimicrob. Agents Chemother. 43:972-974 (1999).Google Scholar
- 23.P. R. Chaturvedi. Pharmacokinetics of microparticulate systems. In S. Cohen, and H. Bernstein (eds.), Microparticulate systems for the delivery of proteins and vaccines, Drugs and the Pharmaceutical Sciences 77, Marcel Dekker, New York, 1996, pp. 321-347.Google Scholar
- 24.J. M. Lanao, M. T. Vicente, L. Sayalero, and A. Dominguez-Gil. A computer program (DCN) for numerical convolution and deconvolution of pharmacokinetic functions. J. Pharmacobiodyn. 15:203-214 (1992).Google Scholar
- 25.S. E. Tett, D. J. Cutler, and R. O. Day. Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. J. Pharm. Sci. 81:155-159 (1992).Google Scholar
- 26.X. Wu, F. Yamashita, and M. Hashida. Deconvolution analysis for absorption and metabolism of aspirin in microcapsules. Biol. Pharm. Bull. 22:1212-1216 (1999).Google Scholar